‡ In these countries please contact our distributor

Expand in Emerging & International Markets

We will deliver market leadership in the Emerging & International Markets by building strong, direct customer relationships and developing products specifically designed for these populations.

("Emerging & International Markets" represent those outside of the Established Markets including Brazil, China, India and Russia.)


The Emerging & International Markets grew at 18% during 2013, exceeding Established Markets rates and contributing half of annual revenue growth for the Group. These geographies now represent 13% of the Group’s overall revenue.

Revenue from Emerging and International Markets1

+18%  $563m

As a percentage of group revenue


During 2013:

  • Our success in China continued with growth of over 30% and now it is our 6th largest country by revenue
  • Significant investment to drive growth organically (e.g. Mexico and Saudi Arabia) and through acquisitions (Brazil, Turkey, India)
  • We put in place our strategy to address the mid-tier market.

Global outlook

The healthcare environment in these markets is rapidly expanding and with the right investments offers significant opportunities for the Group.



2011 includes Clinical Therapies revenue of $237m
2012 includes Clinical Therapies revenue of $107m
1 The underlying percentage increases/decreases are after adjusting for the effect of currency translation and the inclusion of the comparative impact of acquisitions and exclusion of disposals.
2 Explanations of these non-GAAP financial measures are provided on pages 161 to 163 of our 2013 Annual Report.